All Stories

  1. Polypharmacy prevalence, associated factors, and changes over time in Australians with multiple sclerosis
  2. Long-term changes in health-related quality of life among Australian adults with psychological distress: a 16-year perspective
  3. Theoretically explore XRD analysis and multi-functional properties of Ruddlesden popper phase family member Sr2XO4 (X = Ce, Hf, Ti and Zr) for photovoltaic applications
  4. A DFT analysis on the electronic, mechanical, optical, elastic, structural and thermodynamic properties of XBiNb2O7 (X = Cs, Rb, K and Na) for photovoltaic applications
  5. The Uneven Path of Psychological Distress: How Socioeconomic Status Shapes Distress Transitions in Australian Adults
  6. Comorbidity and health-related quality of life among Australian adults with psychological distress: a detailed longitudinal study
  7. Correction: Estimation of Transition Probabilities from a Large Cohort (> 6000) of Australians Living with Multiple Sclerosis (MS) for Changing Disability Severity Classifications, MS Phenotype, and Disease-Modifying Therapy Classifications
  8. Estimation of Transition Probabilities from a Large Cohort (> 6000) of Australians Living with Multiple Sclerosis (MS) for Changing Disability Severity Classifications, MS Phenotype, and Disease-Modifying Therapy Classifications
  9. Exploring the workplace factors and their influence on the employment outcomes for people with multiple sclerosis
  10. The Hidden Toll of Psychological Distress in Australian Adults and Its Impact on Health-Related Quality of Life Measured as Health State Utilities
  11. The economic burden of myalgic encephalomyelitis/chronic fatigue syndrome in Australia
  12. Estimating the disutility of relapse in relapsing–remitting and secondary progressive multiple sclerosis using the EQ-5D-5L, AQoL-8D, EQ-5D-5L-psychosocial, and SF-6D: implications for health economic evaluation models
  13. Long‐term exposure to low concentrations of air pollution and decline in lung function in people with idiopathic pulmonary fibrosis: Evidence from Australia
  14. RWD168 Annual Transition Probabilities for Disease Severity Changes in an Australian Cohort of People with Idiopathic Pulmonary Fibrosis
  15. The influence of immortal time bias in observational studies examining associations of antifibrotic therapy with survival in idiopathic pulmonary fibrosis: A simulation study
  16. The relative contribution of co-morbidities to health-related quality of life of people with idiopathic pulmonary fibrosis using the Assessment of Quality of Life-8-Dimension multi-attribute utility instrument
  17. MS Australia: Progress in MS Research 2022
  18. Maternal choices and preferences for screening strategies of gestational diabetes mellitus: A exploratory study using discrete choice experiment
  19. The economic burden of idiopathic pulmonary fibrosis in Australia: a cost of illness study
  20. Validation of the EQ-5D-5L and psychosocial bolt-ons in a large cohort of people living with multiple sclerosis in Australia
  21. P43 The Economic Burden of Idiopathic Pulmonary Fibrosis in Australia
  22. A gender-specific assessment of tobacco use risk factors: evidence from the latest Pakistan demographic and health survey
  23. Systematic Review and Meta‐Analysis of Health State Utility Values for Osteoarthritis‐Related Conditions
  24. Resource utilization and disaggregated cost analysis of bariatric surgery in the Australian public healthcare system
  25. Healthcare resource utilisation and predictors for critical care unit admissions after primary bariatric surgery in an Australian public hospital setting: an exploratory study using a mixed-methods approach
  26. Impact of remoteness on patient outcomes for people with multiple sclerosis in Australia
  27. Systematic Review of the Evolution of Health‐Economic Evaluation Models of Osteoarthritis
  28. Does health-related quality of life differ between people with relapse onset and progressive onset Multiple Sclerosis?
  29. Comment on: Bariatric surgery is expensive but improves co-morbidity: 5-year assessment of patients with obesity and type 2 diabetes
  30. PMS15 Assessing the Reporting Quality of Studies of Health Economic Evaluation Models in Osteoarthritis
  31. PND38 IMPACT of Remoteness on Cost of Illness of Australians with Multiple Sclerosis
  32. PSU11 Resource Utilization and Disaggregated Cost Analysis of Bariatric Surgery in the Australian Public Healthcare System
  33. Population norms for quality adjusted life years for the United States of America, China, the United Kingdom and Australia
  34. The impact of idiopathic pulmonary fibrosis on health state utility values: evidence from Australia
  35. The impact of comorbidities on health-related quality of life of people with osteoarthritis over 10 years
  36. Cross-sectional and temporal differences in health-related quality of life of people with and without osteoarthritis: a 10-year prospective study
  37. Estimating the relative contribution of comorbidities in predicting health-related quality of life of people with multiple sclerosis
  38. PMU23 Measurement of Health-Related Quality of Life in Australians with Progressive Onset Multiple Sclerosis
  39. PRS18 The IMPACT of Idiopathic Pulmonary Fibrosis on Health State Utility Values: Evidence from Australia
  40. Measuring the health-related quality of life in Australians with multiple sclerosis using the assessment of quality of life-8-dimension (AQoL-8D) multi-attribute utility instrument
  41. The increasing economic burden of multiple sclerosis by disability severity in Australia in 2017: Results from updated and detailed data on types of costs
  42. Does economic prosperity translate to regional youth employment?
  43. Health state utilities for economic evaluation of bariatric surgery: A comprehensive systematic review and meta‐analysis
  44. Bariatric surgery is a cost‐saving treatment for obesity—A comprehensive meta‐analysis and updated systematic review of health economic evaluations of bariatric surgery
  45. Evaluation of the Association Between Health State Utilities and Obesity in Sub-Saharan Africa: Evidence From World Health Organization Study on Global AGEing and Adult Health Wave 2
  46. Change in multiple sclerosis prevalence over time in Australia 2010–2017 utilising disease-modifying therapy prescription data
  47. Modelling the impact of multiple sclerosis on life expectancy, quality-adjusted life years and total lifetime costs: Evidence from Australia
  48. Estimation of annual probabilities of changing disability levels in Australians with relapsing-remitting multiple sclerosis
  49. Health State Utilities and High Body Mass Index: Evidence from who Study of Global Ageing and Adult Health (SAGE)
  50. Life Expectancy, Quality-Adjusted Life Years, and Total Lifetime Costs for Australian People with Multiple Sclerosis
  51. Assessing Health-State Utility Values in Australian People with Multiple Sclerosis
  52. Corrigendum
  53. The impact of multiple sclerosis severity on health state utility values: Evidence from Australia
  54. OECD unbundled local loop pricing
  55. 3G spectrum auction aftermarket network deployment
  56. Do Economic, Institutional, or Political Variables Explain Economic Growth
  57. The Australian digital market: opportunities and challenges